X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.09+0.26 (+9.19%)
Close on Nov 17, 2026Market cap $306.36MP/E –Yield –
X4 Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
X4 Pharmaceuticals's price to sales ratio was 35.7× on Nov 11, 2026, against 16.1× a year earlier. Over the last 3 years it ranged from 2.8× to 57.8×, with a median of 37.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 35.7× | +18.0 |
| 2025 | Dec 31, 2025 | 17.6× | −27.9 |
| 2021 | Apr 30, 2021 | 45.6× | +10.6 |
| 2020 | Dec 31, 2020 | 34.9× | −3.1 |
| 2019 | Dec 31, 2019 | 38.0× | – |
See a number that looks wrong?